Search results for "Platelet"

showing 10 items of 786 documents

A Sequential Algorithm Combining ADAPT and Liver Stiffness Can Stage Metabolic-Associated Fatty Liver Disease in Hospital-Based and Primary Care Pati…

2020

INTRODUCTION Metabolic-associated fatty liver disease is common, with fibrosis the major determinant of adverse outcomes. Population-based screening tools with high diagnostic accuracy for the staging of fibrosis are lacking. METHODS Three independent cohorts, 2 with both liver biopsy and liver stiffness measurements (LSMs, n = 254 and 65) and a population sample (n = 713), were studied. The performance of a recently developed noninvasive algorithm (ADAPT [age, diabetes, PRO-C3 and platelets panel]) as well as aspartate aminotransferase-to-platelet ratio index, fibrosis-4, nonalcoholic fatty liver disease fibrosis score, and LSM was used to stage patients for significant (≥F2) and advanced …

Malemedicine.medical_specialtyBiopsyPopulationGastroenterology03 medical and health sciences0302 clinical medicineFibrosisNon-alcoholic Fatty Liver DiseasePredictive Value of TestsDiabetes mellitusInternal medicineNonalcoholic fatty liver diseasemedicineDiabetes MellitusHumansAspartate Aminotransferaseseducationeducation.field_of_studyHepatologymedicine.diagnostic_testReceiver operating characteristicbusiness.industryPlatelet CountFatty liverGastroenterologyAge FactorsOdds ratioMiddle Agedmedicine.diseaseCollagen Type III030220 oncology & carcinogenesisLiver biopsyElasticity Imaging Techniques030211 gastroenterology & hepatologyFemalebusinessAlgorithmsBiomarkersThe American journal of gastroenterology
researchProduct

Effect of tirofiban on percutaneous coronary intervention-induced endothelial dysfunction in patients with stable coronary artery disease

2004

Recent studies demonstrated that glycoprotein (GP) IIb/IIIa receptor antagonists improve endothelial dysfunction of forearm resistance vessels in patients with stable coronary artery disease. However, it remains unclear whether these findings can be extended to the conductance vessel level. In this study, we aimed to evaluate the acute effect of tirofiban on endothelial function of arterial conductance vessels in patients undergoing percutaneous coronary intervention (PCI). Endothelial function was examined by ultrasonographic measurement of flow-mediated vasodilation (FMD) of the brachial artery. Endothelium-independent vasodilation was determined in response to nitroglycerin. Sixty-six pa…

Malemedicine.medical_specialtyBrachial ArteryEndotheliummedicine.medical_treatmentCoronary Artery DiseasePlatelet Glycoprotein GPIIb-IIIa ComplexCoronary artery diseaseAngioplastymedicine.arteryInternal medicinemedicineHumanscardiovascular diseasesEndothelial dysfunctionBrachial arteryAgedbusiness.industryPercutaneous coronary interventionTirofibanmedicine.diseasemedicine.anatomical_structureTirofibanConventional PCIcardiovascular systemCardiologyTyrosineFemaleEndothelium VascularCardiology and Cardiovascular Medicinebusinessmedicine.drugThe American Journal of Cardiology
researchProduct

Reduced Rivaroxaban Dose Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure: ADRIFT a Randomized Pilot Study.

2020

Background: Percutaneous left atrial appendage closure (LAAC) exposes to the risk of device thrombosis in patients with atrial fibrillation who frequently have a contraindication to full anticoagulation. Thereby, dual antiplatelet therapy (DAPT) is usually preferred. No randomized study has evaluated nonvitamin K antagonist oral anticoagulant after LAAC, and we decided to evaluate the efficacy and safety of reduced doses of rivaroxaban after LAAC. Methods: ADRIFT (Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban in Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure) is a multicenter, phase IIb study, which randomized 105 patients after successful LAAC to eith…

Malemedicine.medical_specialtyCardiac CatheterizationPercutaneousTime FactorsAntithrombin IIIAtrial AppendagePilot Projects030204 cardiovascular system & hematologyFibrin Fibrinogen Degradation Products03 medical and health sciences0302 clinical medicineFibrinolytic AgentsRivaroxabanLeft atrialHeart RateInternal medicineAtrial FibrillationMedicineHumansAtrial Appendage030212 general & internal medicineContraindicationBlood CoagulationAgedAppendageAged 80 and overRivaroxabanbusiness.industryDual Anti-Platelet TherapyAtrial fibrillationThrombosisClopidogrelmedicine.diseasePeptide Fragments3. Good healthTreatment OutcomeCardiologyAtrial Function LeftFemaleProthrombinFranceCardiology and Cardiovascular MedicinebusinessBiomarkersPlatelet Aggregation Inhibitorsmedicine.drugFactor Xa InhibitorsPeptide HydrolasesCirculation. Cardiovascular interventions
researchProduct

Percutaneous closure of left atrial appendage to prevent embolic events in high-risk patients with chronic atrial fibrillation

2009

Background: Percutaneous closure of the left atrial appendage (LAA) is a novel alternative for the treatment of patients with atrial fibrillation (AF) and with a high risk of stroke who are not eligible for long-term anticoagulation therapy. The aim of this study was to asses the safety, feasibility, and long-term efficacy of this procedure. Methods: From July 2004 to June 2007, 20 patients (13 male, mean age 69 ± 8 years) with non–valvular AF (NV-AF) underwent LAA percutaneous closure using the PLAATO™ system, implanted through a transeptal access. All patients had contraindications to anticoagulant therapy and were at high risk for cardioembolic stroke (mean CHADS2 score 3 ± 1.2). A trans…

Malemedicine.medical_specialtyCardiac CatheterizationPercutaneousTime FactorsThromboembolism.left atrial appendage occlusionmedicine.medical_treatmentEmbolismSettore MED/11 - Malattie dell'Apparato CardiovascolareTransesophagealLeft atrial appendage occlusionPericardial effusionRisk AssessmentLeft atrialInternal medicineAtrial FibrillationmedicineHumansRadiology Nuclear Medicine and imagingAtrial Appendageatrial fibrillation; left atrial appendage occlusion; thromboembolism; Aged; Atrial Fibrillation; Contraindications; Echocardiography Transesophageal; Embolism; Equipment Design; Feasibility Studies; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Risk Assessment; Stroke; Time Factors; Treatment Outcome; Anticoagulants; Atrial Appendage; Cardiac Catheterization; Chronic DiseaseStrokeAgedbusiness.industryContraindicationsAnticoagulantsAtrial fibrillationGeneral MedicineEquipment DesignthromboembolismMiddle Agedmedicine.diseaseSurgeryStrokeTreatment OutcomePericardiocentesisEchocardiographyChronic DiseaseCardiologyPatent foramen ovaleFeasibility StudiesFemaleCardiology and Cardiovascular MedicinebusinessEchocardiography TransesophagealPlatelet Aggregation Inhibitors
researchProduct

The treatment of venous leg ulcers: a new therapeutic use of iloprost

2007

Background: We conducted a study using an intravenous (i.v.) infusion of iloprost in the treatment of venous ulcers to verify whether the association of i.v. iloprost + local therapy + elastic compression has a favorable effect when compared with traditional treatment with local therapy and elastic compression. Study Design: We evaluated the effects of iloprost in 98 consecutive patients with noncomplicated venous ulcers of lower limbs subdivided into 2 groups: the first group (48 patients) received iloprost in saline solution for 3 weeks and the second group (50 patients) received a venous infusion of a saline solution. The patients were examined at baseline time 0 (first visit) and then a…

Malemedicine.medical_specialtyElastic compressionmedicine.medical_treatmentIschemiaPlacebo groupDrug Administration Schedulelaw.inventionRandomized controlled triallawmedicineHumansSingle-Blind MethodIloprostInfusions IntravenousVeinSalineDose-Response Relationship Drugbusiness.industryvenous ulcersiloprostLeg UlcerSignificant differenceMiddle Agedmedicine.diseaseCombined Modality TherapySurgeryTreatment Outcomemedicine.anatomical_structureDebridementAnesthesiaAnti-Infective Agents LocalFemaleSurgeryVENOUS LEG ULCERS ILOPROSTbusinessPlatelet Aggregation InhibitorsStockings CompressionIloprostmedicine.drug
researchProduct

Double-blind, crossover study of the clinical efficacy and the hemorheological effects of pentoxifylline in patients with occlusive arterial disease …

1984

The effect of a 3 month daily administration of 800 mg pentoxifylline (Trental 400 bds) or placebo was assessed under double blind crossover design in 18 patients (12 males and 6 females) with peripheral occlusive arterial disease in respect of painfree walking distance and various hemorheological and hemostasiological variables, platelet aggregation, serum cholesterol and triglycerides. In first treatment period walking distance significantly increased with pentoxifylline by 46% from baseline 121 ± 15 m and by 4% with placebo from baseline 134 ± 18 m. Pentoxifylline administration furthermore yielded significant decrease in whole blood and plasma viscosity and significant increase in eryt…

Malemedicine.medical_specialtyErythrocytesPlatelet Aggregationmedicine.medical_treatment030204 cardiovascular system & hematologyPlaceboPentoxifyllineDouble blindPlacebos03 medical and health sciences0302 clinical medicineDouble-Blind MethodMedicineHumansIn patient030212 general & internal medicineClinical efficacyPentoxifyllineTriglyceridesAgedChemotherapyClinical Trials as Topicbusiness.industryOcclusive arterial diseaseIntermittent ClaudicationMiddle AgedBlood ViscosityCrossover studySurgeryAdenosine DiphosphateCholesterolAnesthesiaTheobromineFemaleCollagenCardiology and Cardiovascular MedicinebusinessBlood Flow Velocitymedicine.drugAngiology
researchProduct

Differential effects of isoliquiritigenin and YC-1 in rat aortic smooth muscle.

1997

We investigated the effects of isoliquiritigenin and YC-1 (3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole) on tension in endothelial-free rat aortic rings precontracted with phenylephrine (3 microM). Both compounds induced a concentration-dependent relaxation (EC50 of YC-1 1.9 microM and of isoliquiritigenin 9.4 microM). The effects developed faster with YC-1 than with isoliquiritigenin, and the effects of YC-1 were potentiated by isoliquiritigenin (10 microM). 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one (30 microM) inhibited the effect of YC-1, but not of isoliquiritigenin. These results suggest that the effects of YC-1 are due to stimulation of soluble guanylyl cyclase activity, whereas …

Malemedicine.medical_specialtyIndazolesPhosphodiesterase InhibitorsMuscle RelaxationStimulationMuscle Smooth VascularRats Sprague-Dawleychemistry.chemical_compoundChalconeChalconesAldehyde ReductaseInternal medicinemedicineAnimalsEnzyme InhibitorsPhenylephrinePharmacologybiologyDose-Response Relationship DrugChemistryBiological activityRatsDose–response relationshipEndocrinologyCarotid ArteriesMechanism of actionEnzyme inhibitorGuanylate Cyclasebiology.proteinFemalemedicine.symptomSoluble guanylyl cyclaseIsoliquiritigeninPlatelet Aggregation Inhibitorsmedicine.drugMuscle ContractionEuropean journal of pharmacology
researchProduct

Platelet-activating factor contributes to the induction of long-term potentiation in the rat somatosensory cortex in vitro

2007

The contribution of platelet-activating factor (PAF) to the induction of neocortical LTP was examined in rat brain slices containing the primary somatosensory cortex (SI). Field potentials evoked by single pulse stimulation in cortical layer IV were recorded from layer II/III. In control experiments, tetanic high frequency stimulation (HFS) resulted in input-specific, NMDA receptor-dependent LTP (21.1+/-3.2%; mean+/-SEM; n=15; P0.001). BN-52021 (5 microM), an antagonist at the extracellular PAF receptor, weakened the HFS-induced LTP to 12.4+/-2.7% (n=11; P0.05). In contrast, HFS-induced LTP was significantly enhanced to 29.4+/-2.3% (n=11; P0.05) when brain slices were superfused with ACSF c…

Malemedicine.medical_specialtyLong-Term PotentiationCentral nervous systemStimulationIn Vitro TechniquesBiologySomatosensory systemRats Sprague-Dawleychemistry.chemical_compoundInternal medicineExcitatory Amino Acid AgonistsmedicineAnimalsPlatelet Activating FactorMolecular BiologyPlatelet-activating factorGeneral NeuroscienceValineLong-term potentiationSomatosensory CortexElectric StimulationIn vitroRatsmedicine.anatomical_structureEndocrinologychemistrySynaptic plasticityNMDA receptorNeurology (clinical)NeuroscienceDevelopmental BiologyBrain Research
researchProduct

Combined lymphocyte/monocyte count, D-dimer and iron status predict COVID-19 course and outcome in a long-term care facility

2020

Abstract Background The Sars-CoV-2 can cause severe pneumonia with multiorgan disease; thus, the identification of clinical and laboratory predictors of the progression towards severe and fatal forms of this illness is needed. Here, we retrospectively evaluated and integrated laboratory parameters of 45 elderly subjects from a long-term care facility with Sars-CoV-2 outbreak and spread, to identify potential common patterns of systemic response able to better stratify patients’ clinical course and outcome. Methods Baseline white blood cells, granulocytes’, lymphocytes’, and platelets’ counts, hemoglobin, total iron, ferritin, D-dimer, and interleukin-6 concentration were used to generate a …

Malemedicine.medical_specialtyLymphocyteIronlcsh:MedicineDiseaseMonocyteGeneral Biochemistry Genetics and Molecular BiologyMonocytesFibrin Fibrinogen Degradation ProductsLeukocyte CountLong-term care facilitieInternal medicineD-dimermedicineHumansLymphocytesAgedRetrospective StudiesAged 80 and overbiologybusiness.industryPlatelet CountLong-term care facilitiesClinical outcomeSARS-CoV-2MonocyteResearchlcsh:RCOVID-19Retrospective cohort studyGeneral MedicineBiomarkerMiddle Agedmedicine.diseasePrognosisLong-Term CareFerritinPneumoniamedicine.anatomical_structureTreatment OutcomeD-dimerbiology.proteinFemaleLymphocyteHemoglobinbusinessBiomarkers
researchProduct

Positional brain ischemia with MCA occlusion successfully treated with extra-intracranial bypass.

2010

408 Positional cerebral ischemia (PCI) is an extremely rare condition in which dramatic central nervous system deficits are triggered by standing in patients with severe stenosis or occlusion of the major brain-supplying blood vessels [1] . Because PCI is generally associated with orthostatic hypotension [2, 3] , a hemodynamic mechanism has been proposed [4] . However, PCI has been reported even in patients without orthostatic hypotension [1] . The treatment is medical, but surgery can be considered in refractory cases (endarterectomy for carotid artery stenosis or either highor low-flow extra-intracranial bypass – for carotid occlusion) [3] . We report a case of PCI associated with middle …

Malemedicine.medical_specialtyMiddle Cerebral ArterySettore MED/09 - Medicina InternaTiclopidinePostureIschemiaHemodynamicsOrthostatic vital signsmedicine.arteryInternal medicineParietal LobeOcclusionmedicineHumansThrombophiliacardiovascular diseasesCerebral perfusion pressureTomography Emission-Computed Single-Photonpositional ischemia Extracranial by-passAspirinCerebral Revascularizationbusiness.industryInfarction Middle Cerebral ArteryMiddle Agedmedicine.diseaseMagnetic Resonance ImagingClopidogrelTemporal ArteriesParesisHemiparesisBlood pressureNeurologyIschemic Attack TransientAnesthesiaMiddle cerebral arteryCardiologyNeurology (clinical)medicine.symptomCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation InhibitorsCerebrovascular diseases (Basel, Switzerland)
researchProduct